drugset / Trial / NCT00317434

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

NCT00317434

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose of Lapatinib with Carboplatin AUC 6 in patients with platinum sensitive recurrent ovarian or primary peritoneal carcinoma and to determine the nature and degree of toxicity of Lapatinib in combination with carboplatin AUC 6 in this cohort of patients.

Timeline

Start
2005-11
Primary completion
2007-03
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule 750 mg Oral

Indications